Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New spinal injection aims to tame Huntington's

NCT ID NCT06585449

Disease control Sponsor: Alnylam Pharmaceuticals Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Sep 17, 2026 · Updated 6 times

Summary

This early-stage study tests an experimental drug called ALN-HTT02 in 66 adults with Huntington's disease. The drug is given as a single injection into the spine to see if it is safe and how it affects the body. The goal is to reduce levels of the harmful protein that causes the disease, but this is not a cure—it aims to control the disease over time.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1

The first testing in people. Mainly checks safety and dose, usually in a small group.

Participants

About 66 people

The number the study aims to enrol. It can still change while the study runs.

Started

Oct 2024

Expected to finish

Jul 2028

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

25 to 70 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria * Has stage 2 or early Stage 3 Huntington's disease (HD), per the Huntington's Disease Integrated Staging System (HD-ISS) Exclusion Criteria * Has significant structural or degenerative neurologic disease other than Huntington's Disease (HD) at screening * Has primary or secondary immune compromise at screening due to infections, medical conditions, or chronic therapies * Has alanine aminotransferase or aspartate aminotransferase \>2× upper limit of normal (ULN) * Has an estimated glomerular filtration rate (eGFR) of \<60 mL/min/1.73m\^2 at screening * Has received an investigational agent within the last 1 year or 5 half-lives (if known) Note: other protocol defined inclusion / exclusion criteria apply

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Huntington's disease are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Huntington disease neurodegenerative disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Huntington's disease

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    19 sites in 3 countries. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Clinical Trial Site

    RECRUITING

    Edmonton, T6G 2B7, Canada

  • Clinical Trial Site

    RECRUITING

    Montreal, H2W 1T8, Canada

  • Clinical Trial Site

    RECRUITING

    Ottawa, K1Y4E9, Canada

  • Clinical Trial Site

    RECRUITING

    Vancouver, V6T 2B5, Canada

  • Clinical Trial Site

    RECRUITING

    Berlin, 10117, Germany

  • Clinical Trial Site

    RECRUITING

    Bochum, 44791, Germany

  • Clinical Trial Site

    RECRUITING

    Bonn, 53127, Germany

  • Clinical Trial Site

    RECRUITING

    Dresden, 01307, Germany

  • Clinical Trial Site

    RECRUITING

    Münster, 48149, Germany

  • Clinical Trial Site

    RECRUITING

    Taufkirchen, 84416, Germany

  • Clinical Trial Site

    RECRUITING

    Ulm, 89081, Germany

  • Clinical Trial Site

    RECRUITING

    Birmingham, B15 2TT, United Kingdom

  • Clinical Trial Site

    RECRUITING

    Cambridge, CB2 0PY, United Kingdom

  • Clinical Trial Site

    RECRUITING

    Cardiff, CF103AX, United Kingdom

  • Clinical Trial Site

    RECRUITING

    Glasgow, G51 4TF, United Kingdom

  • Clinical Trial Site

    RECRUITING

    Greater Manchester, M13 9WL, United Kingdom

  • Clinical Trial Site

    RECRUITING

    London, WC1N 3BG, United Kingdom

  • Clinical Trial Site

    RECRUITING

    Oxford, OX3 9DU, United Kingdom

  • Clinical Trial Site

    RECRUITING

    Plymouth, PL6 8DH, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.